药物基本信息
通用名：抗PD-L1单克隆抗体
临床用途：以PD-L1为靶点的免疫调节对抗肿瘤、抗感染、抗自身免疫性疾病及器官移植存活等。
市场需求
在临床上单抗药物的靶向性能够减少正常细胞受损，在减少副作用的同时还增强了药物疗效，所以目前在癌症、自身免疫性疾病、器官移植排斥等领域得到广泛应用。PD-1抗体/PD-L1抗体通过抑制、“狙击”PD-1/PD-L1,阻止其结合，促使抗癌细胞全力清剿癌细胞。
目前已上市的PD-L1新药仅有一种——PD-L1单抗Atezolizumab（Tecentriq）。
The basic information of drug
common name: Anti PD-L1 monoclonal antibody
Clinical use: Immunoregulation using PD-L1 as the target for anti-tumor, anti-infective, anti-autoimmune diseases
and organ transplant survival.
Market demand
In clinical practice, monoclonal antibody targeting can reduce the damage of normal cells, while reducing side effects it also enhances the efficacy of drugs. So it is widely used in cancer, autoimmune diseases, organ transplant rejection and other fields in the current. PD-1 antibody / PD-L1 antibody prevent them combining and promote anti-cancer cells to clear the cancer cells by inhibiting and "sniping" PD-1 / PD-L1.
Currently, there is only one new PD-L1 drug - PD-L1 monoclonal antibody Atezolizumab (Tecentriq).
（抗 PD-L1 单克隆抗体结合 PD-L1 蛋白，图片来源生物谷)
